Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
shCIRH1A lentivirus is a research-grade gene therapy tool consisting of a lentiviral vector that delivers short hairpin RNA (shRNA) specific to the CIRH1A (Cirhin) gene. CIRH1A is a ribosomal protein that is often overexpressed in colorectal cancer and is associated with cell proliferation and survival. The lentivirus-mediated delivery of shRNA triggers the RNA interference (RNAi) pathway, leading to the degradation of CIRH1A mRNA and subsequent knockdown of the Cirhin protein. In preclinical models, such as RKO colorectal cancer cell lines, this knockdown has been shown to inhibit cell growth, induce apoptosis, and cause G1 phase cell cycle arrest. It serves as a molecular tool for studying the oncogenic potential of ribosomal proteins and exploring gene silencing as a therapeutic strategy.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on shCIRH1A lentivirus.